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Abstract
OBJECTIVES: A severe donor organ shortage leads to the death of a substantial number of patients who are listed for transplantation. The
use of hearts from donors after circulatory death could signiﬁcantly expand the donor organ pool, but due to concerns about their viability,
these are currently not used for transplantation. We propose short-term ex vivo normothermic machine perfusion (MP) to improve the via-
bility of these ischaemic donor hearts.
METHODS: Hearts from male Lewis rats were subjected to 25 min of global in situ warm ischaemia (WI) (37°C), explanted, reconditioned
for 60 min with normothermic (37°C) MP with diluted autologous blood and then stored for 4 h at 0–4°C in Custodiol cold preservation
solution. Fresh and ischaemic hearts stored for 4 h in Custodiol were used as controls. Graft function was assessed in a blood-perfused
Langendorff circuit.
RESULTS: During reconditioning, both the electrical activity and contractility of the ischaemic hearts recovered rapidly. Throughout the
Langendorff reperfusion, the reconditioned ischaemic hearts had a higher average heart rate and better contractility compared with un-
treated ischaemic controls. Moreover, the reconditioned ischaemic hearts had higher tissue adenosine triphosphate levels and a trend
towards improved tissue redox state. Perfusate levels of troponin T, creatine kinase and lactate dehydrogenase were not signiﬁcantly lower
than those of untreated ischaemic controls. The micro- and macroscopic appearance of the reconditioned ischaemic hearts were
improved compared with ischaemic controls, but in both groups myocardial damage and oedema were evident.
CONCLUSIONS: Our results indicate that functional recovery from global WI is possible during short-term ex vivo reperfusion, allowing
subsequent cold storage without compromising organ viability. We expect that once reﬁned and validated, this approach may enable safe
transplantation of hearts obtained from donation after circulatory death.
Keywords: Cardiac transplantation • Donation after circulatory death • Organ preservation • Ischaemia–reperfusion • Machine perfusion
INTRODUCTION
Cardiac transplantation is the only curative therapy for end-stage
heart failure, but is limited by a severe shortage of suitable donor
organs. Because of this, it has been estimated that 17% of all
patients listed for cardiac transplantation die before a suitable
donor heart becomes available [1, 2]. Extending graft criteria to
include organs from donation after circulatory death (DCD) could
expand the donor organ pool signiﬁcantly [1].
Although DCD is gaining momentum in solid organ and lung
transplantation [3–5], hearts from DCD donors are generally not
used for transplantation [6, 7]. Consequently, donor hearts are
almost exclusively obtained from brain-dead, heart-beating
donors. During heart-beating donor organ procurement, the
heart is ﬂushed with ice-cold cardioplegic solution directly after
aortic clamping, causing instant cardiac arrest and rapid cooling,
dramatically lowering the heart’s metabolic rate. However,
because the heart’s metabolism does not drop to zero during the
time its oxygen supply is cut-off, intracellular energy stores, in par-
ticular adenosine triphosphate (ATP), are gradually exhausted.
Nevertheless, when the donor hearts is kept immersed in preser-
vation solution at 0–4°C, safe cold storage (CS) up to 4–5 h is pos-
sible [8]. In a typical DCD setting, cardiac arrest is the result of
anoxia upon withdrawal from a ventilator. Because initially, the†Presented at the 27th Annual Meeting of the European Association for Cardio-
Thoracic Surgery, Vienna, Austria, 5–9 October 2013.
© The Author 2014. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.
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heart continues to beat but is devoid of oxygen, myocardial me-
tabolism switches from oxidative to anaerobic, leading to rapid
loss of intracellular ATP, acidosis and accumulation of metabolites,
thereby compromising graft viability [9, 10]. DCD hearts have been
transplanted on a very limited scale [11], but due to concerns
about the combined impact of DCD and the cold ischaemia
inherent to CS, they are generally not used for transplantation.
Normothermic machine perfusion (NMP) has been explored as
alternative to CS in order to improve the function of DCD hearts.
During NMP, the heart is kept in a beating state by continuous
perfusion with warm, oxygenated perfusate [9, 12]. Experimentally,
continuous NMP has enabled recovery from ischaemia and has
improved the viability of hearts from DCD [7, 11, 13, 14]. However,
compared with CS, NMP is far more challenging to implement,
especially during transportation of the donor organ. We have,
therefore, investigated whether an initial period of NMP, during
which the graft can recover from ischaemia, may be combined
with a clinically relevant period of CS, enabling transportation in
an ice chest as usual.
METHODS
All experiments were in compliance with the Swiss and cantonal
legislation regarding humane care of animals. Isoﬂurane (5% for
induction and 2% for maintenance of anaesthesia; Abbott, Baar,
Switzerland) in a 1:1 O2/N2O mixture (PanGas, Dagmarsellen,
Switzerland) was used as anaesthetic for all experiments.
Experimental design
Male Lewis rats (Charles River, Sulzfeld, Germany) weighing 275–
325 g (n = 6 per group) were placed on a heated operating table.
Heparin (1000 IU/kg) (B Braun, Sempach, Switzerland) was given
intravenously, the abdomen was opened with a transverse incision
and 4 ml of blood was collected in syringe containing 500 IU of
heparin. The hearts in the fresh control group were then excised,
ﬂushed with Custodiol and stored on ice while immersed in
Custodiol for 4 h. The hearts in both ischaemic groups were
subjected to 25 min of warm (37°C) ischaemia after inducing
asphyxiation by dissection of the diaphragm and allocated to the
respective preservation protocols (Fig. 1). Following CS, graft
function was assessed in a blood-perfused Langendorff circuit.
Additionally, hearts from each group (n = 5 per group) were
snap-frozen in liquid nitrogen before and after CS for determin-
ation of myocardial ATP and reduced (GSH) and oxidized (GSSG)
glutathione.
Cold storage
Excised fresh and ischaemic hearts were placed in ice-cold saline,
an 18-G cannula (Terumo, Spreitenbach, Switzerland) was posi-
tioned in the aorta, secured with a 4-0 silk ligature and the heart
was slowly ﬂushed with 10 ml of ice-cold preservation solution
(Custodiol; Dr. F. Köhler Chemie, Bensheim, Germany). The hearts
were kept immersed in preservation solution on ice for 240 min.
Perfusion circuit
The perfusion circuit consisted of a jacketed perfusion chamber, an
oxygenator and a heat exchanger, all designed and fabricated spe-
ciﬁcally for this purpose, as well as a peristaltic pump. The oxygen-
ator with a priming volume of 1 ml was constructed with Oxyphan
hollow ﬁbres (Membrana, Wupperthal, Germany) and gassed with
a humidiﬁed gas mixture containing 95% O2/5% CO2 (PanGas). The
total priming volume of the perfusion circuit was8 ml.
Ex vivo reconditioning
Following warm ischaemia (WI), the hearts in the reconditioning
(RC) group were weighed and placed in the perfusion circuit
primed with autologous blood diluted 1:1 with Krebs–Henseleit
buffer containing 10 mmol/l glucose, 117 NaCl, 5.9 KCl, 25
NaHCO3, 1.2 NaH2PO4, 1 CaCl2, 0.512 MgCl2 (all chemicals were
purchased from Sigma-Aldrich Chemie, Buchs, Switzerland) and
500 IU of heparin. Retrograde NMP (37°C) took place at a constant
ﬂow rate of 2.5 ml/g/min for 60 min (see Table 1 for the operating
parameters). ECG (aVL projection) was recorded continuously. At
the end of the RC phase, hearts were removed from the perfusion
circuit, ﬂushed with 10 ml of preservation solution and kept
immersed in preservation solution at 0–4°C for 240 min.
Langendorff reperfusion
At the end of the respective preservation intervals, the hearts
were placed in the perfusion circuit, a balloon-tipped catheter
(Hugo Sachs Elektronik/Harvard Apparatus, March-Hugstetten,
Germany) was inserted into the left ventricle through an incision
in the left atrium and the hearts were perfused in a retrograde
manner for 60 min at 37°C with autologous blood diluted 1:1 with
Krebs–Henseleit buffer at a constant ﬂow rate of 2.5 ml/g/min
(Table 1). After an equilibration period of 10 min, the developed
pressure, heart rate and ECG were continuously recorded with
signal ampliﬁers connected to an analogue–digital transducer
Figure 1: 1Tissue samples taken from all groups prior to cold storage, perfusate samples taken from the WI + Recond group, 2tissue samples taken from all groups fol-
lowing cold storage, and 3tissue and perfusate samples taken from all groups following Langendorff reperfusion. WI: warm ischaemia; CS: cold storage; RP: reperfusion;
RC: reconditioning.
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(Power Lab; ADInstruments, Oxfordshire, UK). Perfusate pO2,
pCO2, haematocrit and pH were monitored using a Stat Proﬁle
pOX Plus blood analyser (Nova Biomedical, Waltham, USA).
Following reperfusion, the hearts were immersed in ice-cold
saline and weighed. The hearts were then divided into four 2–3
mm thick transverse sections, which where snap-frozen in isopen-
tane/liquid nitrogen, or ﬁxed in 4% formaldehyde. Perfusate
samples were centrifuged (16 000 rpm) at 4°C for 2 min, and the
supernatant was pipetted off and stored at −20°C.
Analysis
Graft viability. Myocardial injury was assessed by measuring
the perfusate levels of cardiac troponin T using an
electrochemiluminescent immunoassay and lactate dehydrogenase
and creatine kinase (CK) using an enzymatic UV assay, and K+ was
measured using an ion-selective electrode (all from Roche
Diagnostics, Rotkreuz, Switzerland).
Oxidative stress. The ratio of reduced/oxidized glutathione
(GSH/GSSG) was used to assess tissue redox state as an indicator
of oxidative stress. Tissue samples were homogenized in equal
volumes of solutions containing either 100 mM KCl and 10 mM
MOPS-KOH or 5% trichloroacetic acid in distilled water. After
centrifugation, the supernatant was processed as described in detail
elsewhere [15]. The half-cell redox potential (Ehc) for the GSH:GSSG
couple was then calculated using the following equation:
Ehc ¼ 240 59:55
2
log
½GSH2
½GSSG
where [GSH] and [GSSG] stand for the intracellular GSH and GSSG
content per g wet tissue.
Tissue energy state. Tissue ATP levels of homogenized
myocardial tissue were measured using a bioluminescence kit
(Sigma-Aldrich Chemie). Analysis was performed using a Sirius
luminometer (Berthold Detection Systems, Pforzheim, Germany).
Histology. Tissue slices were ﬁxed in 4% formalin, embedded in
parafﬁn, cut to 4-μm-thick sections and stained with haematoxylin–
eosin. Cell death was evaluated through terminal deoxynucleotide
transferase-mediated dUTP nick-end labelling on 6-μm-thick
formalin-ﬁxed parafﬁn embedded sections using a CardioTACS
in situ apoptosis detection kit (R&D Systems, Abingdon, UK).
Statistical analysis
The mean and maximum heart rate, mean contractility index and
dP/dT of the respective hearts were calculated using the Lab Chart
software (ADInstruments). Comparison between the experimental
groups was performed with the GraphPad Instat.V3.05 software
(GraphPad Software, Inc., La Jolla, USA), using analysis of variance
(ANOVA) with a two-tailed Student’s t-test if the values followed a
Gaussian distribution. If a normality test was not passed, or too
few samples were present to estimate normality, a Kruskal–Wallis
test, followed by a Mann–Whitney test for comparison between
groups (indicated by an § where applicable), was used. All data are
displayed as mean ± 1 SD. The level of statistical signiﬁcance was
set at P < 0.05.
RESULTS
Ex vivo reconditioning
During RC, the hearts resumed sinus rhythm within minutes of
reperfusion. The mean average and mean maximum heart rate
during RC were 149.81 ± 29.55 and 191.48 ± 47.96 bpm, respect-
ively. Perfusate levels of lactate dehydrogenase, CK and troponin
(378.89 ± 190 U/l, 59.22 ± 21.76 U/l and 13.46 ± 4.70 μg/l, respect-
ively) were elevated compared with in vivo reference values, but
were signiﬁcantly lower than those after Langendorff reperfusion
in all groups.
Heart rate and contractility
The mean and maximum heart rates of the reconditioned is-
chaemic hearts were higher than those of the ischaemic con-
trols (145.80 ± 7.31 vs 99.76 ± 24.48 bpm P = 0.0024 respectively
173.18 ± 7.55 vs 137.94 ± 35.27 bpm P = 0.0554), and not signiﬁ-
cantly different from those of cold-stored fresh hearts (Fig. 2A
and B). The reconditioned ischaemic hearts had a higher
mean dP/dT (1687.14 ± 678.39 vs 1288.42 ± 434.48 mmHg/s
P = 0.042) and mean contractile index (6.4 ± 2.88 vs 3.6 ± 0.548/
s P = 0.00653§) than non-treated ischaemic hearts, yet the dif-
ference was not statistically signiﬁcant. No difference existed
between reconditioned ischaemic hearts and cold-stored fresh
controls (Fig. 2C and D).
Myocardial damage
During Langendorff reperfusion of the ischaemic controls, perfus-
ate levels of K+ were signiﬁcantly higher than those of fresh hearts
(5.71 ± 0.20 vs 7.02 ± 0.35 mmol/l P = 0.0084; Fig. 3A). Perfusate
levels of lactate dehydrogenase, CK and troponin T reconditioned
ischaemic hearts were not signiﬁcantly different from those of
cold-stored ischaemic controls (Fig. 3B–D).
Tissue energy state
Fresh-excised hearts had a tissue ATP content of 12.11 ± 2.07
μmol/g. Myocardial ATP dropped almost 10-fold to 1.40 ± 0.93
μmol/g after 25 min of WI. One hour of RC replenished ATP levels
Table 1: Operating parameters during reconditioning and
Langendorff reperfusion
Temperature (°C) 37
Flow rate (ml/g/min) 2.5
pO2 (mmHg) 150–250
pCO2 (mmHg) 35–45
pH 7.3–7.4
Haemoglobin (g/dl) 6–7
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to 8.01 ± 2.10 μmol/g (Fig. 4). During 4 h of CS, the ATP level of
fresh and reconditioned ischaemic hearts dropped at a similar
rate (1.56 vs 1.61 μmol/g/h) to 5.87 ± 1.65 and 1.75 ± 0.48 μmol/g,
respectively. Both values were signiﬁcantly higher than those of
ischaemic hearts (0.53 ± 0.10 μmol/g P = 0.0159 respectively
P = 0.0159§). After Langendorff reperfusion, tissue ATP of both
cold-stored fresh and reconditioned hearts was signiﬁcantly
higher than that of untreated cold-stored ischaemic controls
(8.11 ± 2.19 P = 0.0004 respectively 5.75 ± 1.97 P = 0.031 vs
3.93 ± 0.95 μmol/g; Fig. 4).
Figure 2: The mean (A) and maximum heart rates (B), mean contractile index (C) and dP/dT (D) of fresh, ischaemic and reconditioned ischaemic hearts during
Langendorff reperfusion.
Figure 3: Perfusate concentrations of K+ (A), LDH (B), troponin T (C) and CK (D) of fresh, ischaemic and reconditioned ischaemic hearts during Langendorff reperfu-
sion. LDH: lactate dehydrogenase; CK: creatine kinase.
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Oxidative stress
After CS and following Langendorff reperfusion, the reconditioned
ischaemic heart’s tissue GSH content was 1152.133 ± 103.55 respect-
ively 686.65 ± 141.62 nmol/g, compared with 950.08 ±103.55 re-
spectively 634.96 ± 103.47 nmol/g in the ischaemic control group
(P = 0.377 respectively P = 0.401). The tissue redox state of the
reconditioned ischaemic hearts, expressed as half-cell redox poten-
tial for the GSH–GSSG couple, was −264.43 ± 8.05 respectively
−252.26 ± 3.33 mV at these time points. These values did not differ
signiﬁcantly from the values in the ischaemic control group
(−263.10 ± 5.83 respectively −251.58 ± 3.10 mV P = 0.791 respective-
ly P = 0.672).
Histology
Compared with cold-stored fresh controls, the reconditioned is-
chaemic hearts showed minimal focal necrosis and oedema and
cold-stored ischemic hearts showed widespread damage, oedema
and extensive areas of infarction (Fig. 5). Fewer terminal deoxynu-
cleotide transferase-mediated dUTP nick-end labelling-positive
nuclei per slide were visible in reconditioned ischaemic hearts
compared with cold-stored ischaemic hearts (73.66 ± 36.53 vs
134 ± 23.49 nuclei/slide P = 0.0341), but their number was
increased compared with cold-stored fresh controls (39.6 ± 12.32
P = 0.0074).
DISCUSSION
Machine perfusion (MP) has been investigated as a method for
donor heart preservation since cardiac transplantation’s early
years. With the advent of advanced organ preservation solutions
that permitted extended CS without compromising graft viability,
MP was soon abandoned due to its complexity. Driven by the
need for a preservation method that allows recovery and safe
transplantation of hearts from DCD donors, MP has gained
renewed interest. Two main MP approaches can be distinguished:
hypothermic machine perfusion and NMP. During hypothermic
machine perfusion, the heart is perfused with an oxygenated car-
dioplegic solution at 0–4°C. Hypothermic machine perfusion
relies on the same principle as CS: cardioplegic arrest and cooling
in order to minimize myocardial oxygen demand during preser-
vation [9, 10]. During NMP, on the other hand, the heart is kept in
a beating state by continuous perfusion with warm, oxygenated
perfusion medium. Compared with CS, both hypothermic
machine perfusion and NMP have enabled extended preservation
and improved organ viability. However, because NMP’s near
physiological conditions allow temperature-dependent adaptive
and reparative processes to take place, it is an ideal approach to
recover organs after DCD. Nevertheless, compared with both CS
and hypothermic machine perfusion, NMP is much more challen-
ging to implement; a device capable of maintaining the heart in a
beating state is likely to be difﬁcult to transport and may require
Figure 4:Myocardial ATP content of fresh, ischaemic and reconditioned ischae-
mic hearts before cold storage, after 4 h of cold storage and after Langendorff
perfusion. ATP: adenosine triphosphate.
Figure 5: Representative haematoxylin–eosin stained slides of fresh, ischaemic and reconditioned ischaemic hearts after Langendorff perfusion at 5× (A) and 20× (B)
magniﬁcation. Arrows indicate tissue destruction/necrosis, asterisks indicate infarctions and stars indicate contraction bands.
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constant monitoring, and malfunction during transportation could
easily lead to loss of the graft.
To avoid these issues, we have assessed whether a short period
of NMP directly following exposure to WI could reverse WI’s
harmful effects, permitting ensuing CS without jeopardizing graft
viability. Following NMP, the reconditioned ischaemic hearts were
stored for 4 h in cold preservation solution, after which graft
performance was assessed in a blood-perfused Langendorff circuit
and compared with that of cold-stored fresh and ischaemic
controls.
Our results indicate that 1 h of ex vivo NMP enabled recovery of
the heart’s function and metabolic state to near-normal levels.
During NMP, the hearts rapidly resumed sinus rhythm after a brief
period of bradyarrhythmia. An initial drop in perfusate pH and
rise in perfusate lactate levels were seen, and although the perfus-
ate levels of lactate dehydrogenase, CK and troponin T were ele-
vated compared with in vivo reference values, they were markedly
lower than the same values of fresh cold-stored hearts during
Langendorff reperfusion. This suggests that 4 h of CS by itself
caused more myocardial damage than 25 min of WI, and that
the combination of WI and CS is particularly harmful. During
Langendorff reperfusion, both the heart rate and contractility
of the reconditioned ischaemic hearts were higher than those
of cold-stored ischaemic hearts and no different from those of
fresh-excised cold-stored controls. However, in all groups, the
mean maximum heart rate was lower than typical in vivo values.
We found that 25 min of WI led to an almost 10-fold reduction
in tissue ATP. Although the impact of global WI on myocardial ATP
is debated [16], ATP depletion is generally accepted as an import-
ant contributor to ischaemia–reperfusion damage. During one
hour of normothermic reperfusion, tissue ATP levels were replen-
ished to approximately two-thirds of those measured in freshly
excised hearts, sufﬁcient etc. to prevent ATP depletion during
ensuing CS. Interestingly, both fresh-excised hearts and reperfused
ischaemic hearts showed a constant rate of ATP decline during CS.
ATP replenishment and hence tolerance to additional ischaemia
during preservation and reimplantation may be further improved
by fortifying the perfusate with metabolic substrates such as Krebs
cycle intermediates and branched chain amino acids [16–19],
which have shown to stimulate ATP synthesis during MP [20].
Oxidative stress is also seen as an important mediator of the
damage after exposure to WI [21, 22]. However, we found no sig-
niﬁcant differences in the levels of GSH and tissue redox potential
between the experimental groups. Nevertheless, oxidative stress
during reperfusion may be reduced by using leucocyte-depleted
blood as perfusate, shown to improve organ viability during MP
[23], as well as by continuous delivery of antioxidants and radical
scavengers during RC.
Both reconditioned ischaemic hearts and cold-stored ischaemic
controls showed signs of inhomogeneous tissue perfusion, infarc-
tion and oedema. Tissue perfusion during RC may be improved
by an initial ‘hot shot’ of cardioplegia, aimed at reducing myocar-
dial oxygen demand during early reperfusion when the heart’s
microcirculation may still be compromised by post-ischaemic
stunning and vasoconstriction. Focal ischaemia due to thrombi
formation may be prevented by administering thrombolytic com-
pounds such as strepktokinase or thrombokinase during RC. Both
the increased hydrostatic pressure during MP and the use of
diluted blood as medium may have contributed to the tissue
oedema we observed in all groups after reperfusion. This may be
prevented by addition of compounds that increase the perfusate’s
oncotic pressure, such as dextrans or albumin [24].
We chose 37°C for RC, because we hypothesized that mimick-
ing physiological conditions would permit optimal recovery from
ischaemia. However, whether normothermia is necessary and
even desirable remains to be investigated. It is conceivable that
the protective effect of mild hypothermia commonly used in
cardiac surgery may also be of beneﬁt to our approach.
Limitations of our approach
Although our in vivo model of WI more closely mimics a clinical
DCD setting than other models [25], an ex vivo WI model may
provide better control of both the duration and temperature of
WI, thereby improving reproducibility. Moreover, since the heart
is unloaded during the Langendorff reperfusion, myocardial
damage might be underestimated, and because only left ventricu-
lar function is assessed, WI’s impact on right ventricular function
remains unknown. Even though this study is a proof of principle of
the potential beneﬁt of NMP after global WI, further reﬁnement
and validation of this approach are needed before testing in a
large animal model is sensible.
CONCLUSION
Our ﬁndings indicate when 25 min of WI is immediately followed
by 60 min of ex vivo reconditioning, WI’s negative impact is signiﬁ-
cantly ameliorated, enabling subsequent CS without compromis-
ing organ viability. Replenishment of intracellular ATP to near-
normal levels during reperfusion, preventing ATP depletion
during the CS interval, appears to be an important contributor to
NMP’s beneﬁcial effect. We envision that a similar approach may
eventually enable safe transplantation of hearts from DCD donors.
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APPENDIX. CONFERENCE DISCUSSION
Dr M. Erasmus (Groningen, Netherlands): It’s really a great challenge to use
these kind of donors to expand the donor pool, and many researchers are busy
ﬁnding out what the best options are. You chose warm reperfusion at, I think,
the right time, immediately after the ischaemia. Why did you choose this nor-
mothermic reperfusion and not, say, 34 or 30 degrees as many others do?
Dr Tolboom: Well, I have two answers to that question. I’ve occupied myself
with normothermic and sub-normothermic reperfusion for donor liver pro-
curement and recovery since 2004, so I’m intimately familiar with what’s
needed to do this, so I just did what comes best, what’s familiar to me.
The second part of the answer is that currently I’m looking at the whole spec-
trum between 20 and 37 degrees, and my intuition and my preliminary results
say that actually the optimum temperature is somewhere between room tem-
perature and normothermic. It’s looking like 25 degrees is actually a very good
temperature. If I go lower than 20, results aren’t good, and actually the results
of 37 degrees don’t look as good as the results when I go a bit lower, like
25 degrees.
Dr Erasmus: Yes. But then in this research it looked like the warm reperfusion
was as good as the control group because all the results were comparable, and
only the cold storage did the damage. Did you expect that the cold storage
would have such an impact on the damage?
Dr Tolboom: No, I did not. And with the cold stored group you mean, the
group that was my control?
Dr Erasmus: Yes.
Dr Tolboom: I did not, no. I hadn’t expected it, which I pointed out in the
paper, I didn’t show the results in the slides due to time limitations. When com-
paring the myocardial damage markers, the soluble ones in the perfusate,
between the fresh hearts during Langendorff and the ischaemic hearts during
the ﬁrst reconditioning phase, the damage was way lower in the latter group.
So 25 min of warm ischaemia inﬂicted way less damage than four hours of cold
storage on healthy hearts. I didn’t expect that.
Dr Erasmus: Oh, it surprised you also?
Dr Tolboom: It’s an interesting ﬁnding, yes.
Dr Erasmus: My last question relates to the composition you used. You used
blood and then diluted it.
Dr Tolboom: Yes.
Dr Erasmus: As others showed, especially German investigators, it’s critical to
have no leukocytes in this ﬁrst reperfusion, and you do not mention a word
about leukocytes.
Dr Tolboom: Yes. I recently recommenced this research in this ﬁeld, and the
goal of these experiments was to establish baseline parameters, and I hadn’t
expected that it would work so well. And that’s what I did in my previous career
in research doing the liver reperfusions; I leukocyte-depleted them. So that is
something I’m going to be looking at. This is a very bare bones basic approach.
Krebs-Henseleit mixed with blood is probably one of the worst conceivable
perfusion solutions which makes its beneﬁcial effects even more impressive to
me. But deﬁnitely, yes, leukocytes are probably something that you want to
avoid in a clinical setting.
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